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Dr H. Edward Garrett Jr, MD (Memphis, Tenn): I congrat-
ulate you on an excellent presentation and congratulate the Emory
group for a robust experience with thoracic aortic endografting.
This is a retrospective analysis of a single-center experience aimed
at evaluating the risk factors contributing to 30-day and late
mortality following thoracic aortic endografting for a wide variety
of aortic pathologies.
The authors conclude that several factors independently pre-
dict mortality after thoracic endovascular aortic repair (TEVAR) by
multivariate analysis. Of course, it is no surprise that rupture is
associated with increased 30-day mortality. Among elective cases,
concurrent debranching, size of aneurysm, and white count
10,000 were all independent predictors of mortality.
There are multiple reports documenting the increased mor-
bidity and mortality associated with debranching procedures.
Probably this procedure should be reserved for specific individual
situations. Although increased aneurysm diameter correlates with
increased risks, I do not believe that this will change our practice
patterns. In my mind, the patient with the larger aneurysm is the
one most needing urgent repair who I can also offer the most
benefit from repair.
This leaves us with the most intriguing conclusion from this
data: patients with a preoperative white count 10,000 have
increased 30-day and all-cause mortality. This finding has been
previously documented in multiple studies for coronary artery
disease, stroke, and lower extremity ischemia, but to my knowl-
edge (someone can correct me if I am wrong), this is the first
evidence that an elevated white count produces increasedmortality
for thoracic aortic pathology. In the previous reports of increased
morbidity and mortality in coronary, cerebrovascular, and lower
extremity ischemia patients, the elevated white count appeared to
be a marker of systemic inflammation and the mechanism of death
was small vessel thrombosis associated with myocardial infarction
or stroke. It was assumed that an elevated white count was associ-
ated with platelet activation, endothelial dysfunction, compliment
activation, and/or oxidative injury resulting in small vessel throm-
bosis.
It would be very interesting to know, therefore, if an elevated
white count in patients with thoracic aortic pathology resulted in
the same increased risk of myocardial infarction and stroke or was
associated with aneurysm-related complications. Unfortunately,
the cause of death was unknown in 45% of your patients, which is
the most disappointing limitation of this study. In patients with
elevated white count in whom the cause of death was known, whatwas that cause? In addition, it was unclear to me if patients with
mycotic aneurysm or recent trauma (who might be expected to
have an elevated white count) were included in this asymptomatic
subgroup analysis, which may have skewed the interpretation.
Could you clarify this?
So what does this mean for our practice? Should we delay
surgical treatment in patients with an elevated white count? Should
we explore treatment options to actively decrease their white
count? Or is elevated white counts simply a byproduct of obesity
and smoking? In conclusion, will this information change your
clinical practice? I enjoyed the manuscript and appreciated receiv-
ing it in a timely fashion, and I appreciate the privilege of opening
this discussion.
Dr Corriere. Thank you very much for your insightful ques-
tions. We did not specifically model postoperative myocardial
infarction or stroke as outcomes, so I can’t really answer that
question for you at this time. As for specific causes of death, the
majority of deaths (in those patients where a cause could be
ascertained) were due to myocardial infarction; this was the cause
of death in about a third of the patients. Renal failure was another
common cause of death, although as you said, cause of death was
unknown in many cases. There were a subset of patients who
succumbed to complications related to subsequent abdominal
aortic aneurysm repair, and these were counted as aneurysm-
related mortalities. We did not exclude mycotic aneurysms or
aortic repairs related to traumatic injury; although they comprised
a minority of the indications for repair, neither had a significant
univariate association with mortality in this analysis.
What does it mean in our practice? Apart from risk stratifica-
tion, I am not sure. Literature related to leukocytosis in patients
with cardiovascular disease hypothesizes that administration of
hydroxyurea or antagonism of selectin and/or integrin receptors
may be future therapeutic strategies, but I have not observed any
published reports of successful reduction in procedural mortality
or complications resulting from specific therapies of this nature. I
think it is fascinating that there are specific benefits of statin use in
patients with coronary artery disease and leukocytosis. This does
not specifically change management of the majority of patients
undergoing thoracic aortic repair, however, as nearly all these
patients should be on statin medications anyway. To summarize,
the patient with leukocytosis who needs an aortic repair is at
increased risk for mortality, but apart from ruling out or treating
any acute infection, we cannot recommend any other specific
management based on this analysis.
